3.57
Schlusskurs vom Vortag:
$3.6475
Offen:
$3.65
24-Stunden-Volumen:
9,926
Relative Volume:
0.16
Marktkapitalisierung:
$5.51M
Einnahmen:
$2.54M
Nettoeinkommen (Verlust:
$-4.13M
KGV:
-1.2982
EPS:
-2.75
Netto-Cashflow:
$-4.11M
1W Leistung:
-4.54%
1M Leistung:
+28.42%
6M Leistung:
-17.36%
1J Leistung:
-15.70%
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Firmenname
Xenetic Biosciences Inc
Sektor
Branche
Telefon
781-778-7720
Adresse
945 CONCORD ST., FRAMINGHAM, MA
Vergleichen Sie XBIO mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
XBIO
Xenetic Biosciences Inc
|
3.57 | 5.77M | 2.54M | -4.13M | -4.11M | -2.75 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2020-01-08 | Eingeleitet | Maxim Group | Buy |
Xenetic Biosciences Inc Aktie (XBIO) Neueste Nachrichten
Xenetic Biosciences Inc. Stock Analysis and ForecastFree Risk Assessment Services - jammulinksnews.com
What analysts say about Xenetic Biosciences Inc. stockRobust investment performance - jammulinksnews.com
What drives Xenetic Biosciences Inc. stock priceExceptional market positioning - jammulinksnews.com
Is Xenetic Biosciences Inc. a good long term investmentConsistently exceptional gains - jammulinksnews.com
Why Xenetic Biosciences Inc. stock attracts strong analyst attentionLow Risk High Reward Picks - Newser
What makes Xenetic Biosciences Inc. stock price move sharplyFree Exclusive Investment Tips - Newser
How Xenetic Biosciences Inc. stock performs during market volatilityOptimized Return Investment Picks - Newser
Xenetic Biosciences (NASDAQ:XBIO) Shares Down 8% – What’s Next? - Defense World
Head to Head Comparison: Xenetic Biosciences (NASDAQ:XBIO) versus Vaxart (NASDAQ:VXRT) - Defense World
Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic C - The Holland Sentinel
New to The Street Announces Media Coverage of BitMine Immersion Technologies Inc., Including NewsOut Video PR Integration - Great Falls Tribune
North Shore Uranium Engages Investing News Network - Great Falls Tribune
LQR House Announces Strategic Marketing Cooperation with Montauk Distilling Co. for Cinnamon Flavored Rum - Great Falls Tribune
Monogram Technologies Announces the Mandatory Conversion of 8.00% Series D Convertible Cumulative Preferred Stock - Great Falls Tribune
Groundbreaking Pancreatic Cancer Trial Launches: DNase I Combined With FOLFIRINOX in Advanced Cases - Stock Titan
Unusual Machines Inc. Promotes Stacy Wright to Executive Vice President of Revenue as Company Scales U.S. Footprint and Prepares for Accelerated Growth - Great Falls Tribune
Xenetic Biosciences’ 13.5% Surge: What’s Driving the Unexplained Rally? - AInvest
Pre-market Movers: NKTR, INM, IBIO, IBO... - RTTNews
Why Did Cyclacel Pharmaceuticals Inc. (CYCC) Soar 13.92%? - AInvest
Xenetic Biosciences Reports Improved Q1 2025 Results - TipRanks
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update - Defense World
Canaccord Genuity Group Issues Pessimistic Forecast for Annovis Bio (NYSE:ANVS) Stock Price - Defense World
Head-To-Head Survey: Xenetic Biosciences (NASDAQ:XBIO) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Equities Analysts Set Expectations for XBIO Q2 Earnings - Defense World
Xenetic Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Xenetic (XBIO) Reports Strong Revenue Growth for Q1 | XBIO Stock News - GuruFocus
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial R - GuruFocus
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - ACCESS Newswire
Xenetic Reports 16% Revenue Growth, Expands Cancer Drug Development with New Clinical Partnerships - Stock Titan
Finanzdaten der Xenetic Biosciences Inc-Aktie (XBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):